NAFLD as a continuum: from obesity to metabolic syndrome and diabetes

Overview of attention for article published in Diabetology & Metabolic Syndrome, July 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#13 of 804)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 13 news outlets
blogs: 1 blog

twitter: 5 X users

Citations

dimensions_citation: 332 Dimensions

Readers on

mendeley: 545 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 14 news stories from 13 outlets.

SURVODUTIDE PHASE II TRIAL SHOWS 83% OF ADULTS TREATED ACHIEVED GROUNDBREAKING RESULTS IN LIVER DISEASE DUE TO MASH, WITH SIGNIFICANT IMPROVEMENTS IN FIBROSIS

Agência Estado, 26 Feb 2024

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after…

News story from Finanz Nachrichten on Monday 26 February 2024

Finanz Nachrichten, 26 Feb 2024

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Le Lézard, 26 Feb 2024

Boehringer Ingelheim today announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically…

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Yahoo! Finance USA, 26 Feb 2024

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 10 additional news stories.